New US ECCNs: tighter controls on biotech equipment

The Bureau of Industry and Security (BIS) has introduced two new ECCNs within the EAR, marking a significant shift in how sensitive biotechnology equipment is controlled. This update reflects the growing strategic importance of advanced bio-analytical tools and the need to limit their potential misuse in high-risk environments.

What is changing

Several categories of equipment that were previously covered under the more flexible ECCN 3A999 are now reclassified under ECCN 3A069. This includes high-capacity flow cytometers and advanced mass spectrometers used in top-down proteomics, two technologies whose performance levels make them critical from a national security perspective.

In parallel, BIS has created ECCN 3E069, which introduces controls on the technical know-how associated with the development and manufacturing of this equipment. The intention is clear: limiting not only the export of the hardware itself, but also the transfer of the expertise needed to reproduce it.

Impact on exporters

Exporters will face stricter requirements.
New restrictions apply for national security, regional stability and anti-terrorism reasons.
Licences will now be required for destinations such as China, Russia or Iran, and certain country groups face a presumption of denial, particularly D:1 and D:5.
Companies exporting to Group D countries must also complete an EEI filing, adding an additional layer of compliance.

Effective date: January 16, 2025
Public comment period: until March 17, 2025

With these new classifications, the United States aims to reinforce the global framework for dual-use biotechnology controls. For companies operating internationally, these updates may require an adjustment of internal processes, supplier relationships and risk assessments to maintain compliance.

How could these regulatory changes affect the resilience of your supply chain?